Primary outcomes were Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), physician global assessment (PGA), interleukins (IL-6, IL-17, IL-23, IL-22), and adverse events. The gene discussed is IL22; the disease is psoriasis.